Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20355)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | GR50 | GRmax | GR_AOC | GEC50 | GRinf | GR Hill Coefficient | GR r2 | pval_GR |
|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-436 | AZD6738 | -inf | |||||||
| HCC1500 | AZD6738 | -inf | -0.9469 | ||||||
| HCC1954 | BMS-265246 | -inf | -0.1012 | ||||||
| HCC1500 | RO-3306 | -inf | -0.9896 | ||||||
| HCC1500 | THZ531 | -inf | -0.9990 | ||||||
| HCC1500 | Ulixertinib | -inf | 0.3396 | ||||||
| HCC1500 | Alvocidib | -inf | -0.9990 | ||||||
| MDA-MB-157 | Ulixertinib | -inf | 0.3233 | ||||||
| SK-BR-3 | BMS-265246 | -inf | 0.0240 | ||||||
| HCC1500 | Senexin B | -inf | -0.9794 | ||||||
| BT-549 | RO-3306 | -inf | -0.1143 | ||||||
| HCC1500 | GSK2334470 | -inf | -0.7194 | ||||||
| MCF7 | Alvocidib | -inf | -0.2526 | ||||||
| HCC1500 | SHP099 | -inf | -0.1868 | ||||||
| MDA-MB-157 | MK 1775 | -inf | -0.8758 | ||||||
| T47D | Ribociclib | -inf | 0.0709 | ||||||
| MDA-MB-134-VI | SHP099 | -inf | 0.8081 | ||||||
| MDA-MB-134-VI | Senexin B | -inf | 0.2609 | ||||||
| MDA-MB-134-VI | Rucaparib | #NAME? | 0.6274 |